Psoriasis Treatment Market: Market Growth and Revenue Forecast 2024-2032
The global psoriasis treatment market is projected to expand significantly, with valuations increasing from USD 28.15 billion in 2023 to an estimated USD 54.87 billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2024-2031.
Market Overview
Psoriasis, a chronic autoimmune condition characterized by rapid skin cell proliferation leading to red, scaly patches, has seen a rising prevalence worldwide. Factors such as immune system irregularities, genetic predispositions, and environmental triggers—including smoking, stress, and infections—contribute to the onset of various psoriasis types, including plaque, scalp, nail, and guttate psoriasis. The increasing incidence of this non-communicable disease underscores the urgent need for effective treatment solutions.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/2828
Regional Analysis
- North America: Dominates the market with a 74.57% share in 2023, attributed to a high number of individuals affected by skin disorders and robust healthcare infrastructure.
- Europe: Experiencing rapid growth due to heightened awareness, early diagnosis, and favorable health policies supporting advanced therapies.
- Asia-Pacific: Anticipated to witness significant expansion, driven by increased awareness, improved diagnostic rates, and a focus on advanced treatment options.
Market Segmentation
The psoriasis treatment market is segmented based on:
- Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, and others.
- Type: Plaque Psoriasis, Psoriatic Arthritis, and others.
- Route of Administration: Oral, Parenteral/Systemic, and Topical.
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Key players
The major key players are AbbVie Inc, Novartis AG, Merck & CO, Inc, Amgen, UCB, Sun pharmaceutical Industries Ltd., Pfizer, Johnson & Johnson, Eli Lilly and Company, Leo pharma A/S and others.
Key Highlights
- Market Growth: Projected CAGR of 8.7% from 2024 to 2031, with market size expected to reach USD 54.87 billion by 2031.
- Regional Dominance: North America leads with a 74.57% market share in 2023.
- Government Initiatives: Programs like the Psoriasis Prevention Initiative (PPI) by the National Psoriasis Foundation (NPF) are investing approximately $6.5 million to enhance clinical support and awareness.
- Challenges: High treatment costs and lack of awareness, especially in developing regions, hinder market growth.
Future Outlook
The psoriasis treatment market is on a trajectory of robust growth, propelled by increased disease prevalence and proactive governmental and organizational initiatives aimed at improving patient outcomes. Advancements in biologic therapies and personalized medicine are anticipated to offer more effective and targeted treatment options. However, addressing challenges such as high treatment costs and enhancing awareness, particularly in underdeveloped regions, remains crucial. Collaborative efforts among healthcare providers, policymakers, and pharmaceutical companies are essential to make treatments more accessible and affordable, thereby improving the quality of life for those affected by psoriasis.
Conclusion
The escalating global burden of psoriasis necessitates concerted efforts to advance treatment modalities and accessibility. With promising growth prospects, the psoriasis treatment market is poised to make significant strides in addressing this pervasive health concern, ultimately aiming to enhance patient care and outcomes worldwide.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian